INTS Stock Analysis: Buy, Sell, or Hold?
INTS - Intensity Therapeutics, Inc. Common stock
$3.71
-0.22 (-5.60%)
▼
5d:
+0.0%
30d:
-19.87%
90d:
-42.84%
BUY
HIGH Confidence
Analysis Updated: Jun 16, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When INTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: INTS shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: INTS shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: INTS is currently trading at $3.71, which is considered oversold relative to its 30-day fair value range of $3.88 to $4.79.
Technical Outlook: Technically, INTS is in a downtrend. Immediate support is located at $3.51, while resistance sits at $4.66. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $24.80 (+568.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INTS is in a downtrend. Immediate support is located at $3.51, while resistance sits at $4.66. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $24.80 (+568.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.88 -
$4.79
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.6%)
- BULLISH: Trading 568.5% below Wall St target ($24.80)
Trading Range Analysis
30-Day Trading Range
$3.88 -
$4.79
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.51
Resistance Level
$4.66
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.37
Wall Street Target
$24.80
(+568.5%)
Share & Embed Analysis
Last updated: June 16, 2026 6:34 PM ET
Data refreshes hourly during market hours. Next update: 7:34 PM
Data refreshes hourly during market hours. Next update: 7:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 64 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 63 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 60 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 61 BUY |
